These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 33228575)

  • 21. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia.
    Ranjbar F; Sadeghi-Bazargani H; Niari Khams P; Arfaie A; Salari A; Farahbakhsh M
    Neuropsychiatr Dis Treat; 2015; 11():549-55. PubMed ID: 25784810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials.
    Takeuchi H; Fathi A; Thiyanavadivel S; Agid O; Remington G
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29570965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
    Jeong HG; Lee MS; Lee HY; Ko YH; Han C; Joe SH
    Int Clin Psychopharmacol; 2012 Jul; 27(4):177-83. PubMed ID: 22407277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
    Chen CK; Huang YS; Ree SC; Hsiao CC
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
    Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
    Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
    Chan CH; Chan HY; Chen YC
    Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
    Robinson DG; Gallego JA; John M; Petrides G; Hassoun Y; Zhang JP; Lopez L; Braga RJ; Sevy SM; Addington J; Kellner CH; Tohen M; Naraine M; Bennett N; Greenberg J; Lencz T; Correll CU; Kane JM; Malhotra AK
    Schizophr Bull; 2015 Nov; 41(6):1227-36. PubMed ID: 26338693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.
    Qiao Y; Yang F; Li C; Guo Q; Wen H; Zhu S; Ouyang Q; Shen W; Sheng J
    Psychiatry Res; 2016 Mar; 237():83-9. PubMed ID: 26921057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia.
    Ma CH; Chan HY; Hsieh MH; Liu CC; Liu CM; Hwu HG; Kuo CH; Chen WJ; Hwang TJ
    Ther Adv Psychopharmacol; 2022; 12():20451253211064396. PubMed ID: 35111295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
    Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
    Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study.
    Kanahara N; Takase M; Sasaki T; Honma M; Fujita Y; Tadokoro S; Suzuki H; Yamanaka H; Noda S; Yanahashi S; Saiga T; Komatsu N; Simoyama T; Iyo M
    Int Clin Psychopharmacol; 2020 Nov; 35(6):338-344. PubMed ID: 32868522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review.
    Druyts E; Zoratti MJ; Toor K; Wu P; Kanji S; Rabheru K; Mills EJ; Thorlund K
    BMC Pediatr; 2016 Nov; 16(1):181. PubMed ID: 27825323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.